β-Arrestins and disease-linked variants: opportunities for targeted modulation

Area of Science:

• Pharmacology
• Molecular Biology
• Biochemistry

Background:

• G protein-coupled receptors (GPCRs) are major drug targets, but their regulators, β-arrestins, are less understood.
• Limited isoform selectivity and few modulators exist for β-arrestins, despite their roles in receptor desensitization, trafficking, and signaling.

Purpose of the Study:

• To review β-arrestin biology, signaling, and recent advances in their modulation.
• To discuss emerging strategies for developing selective arrestin-targeting drugs, with an emphasis on peptides.

Main Methods:

• Literature review of β-arrestin biology, signaling pathways, and drug discovery efforts.
• Analysis of recent findings on disease-associated mutations and β-arrestin modulators.
• Exploration of peptide design and small-molecule approaches for direct β-arrestin targeting.

Main Results:

• Advances in small-molecule and peptide design enable direct β-arrestin modulation.
• Identification of disease-associated mutations and first-generation modulators offers new targeting opportunities.
• Precision drug development strategies are emerging for arrestin-targeting compounds.

Conclusions:

• Direct modulation of β-arrestins presents a promising avenue for therapeutic intervention.
• Peptide-based ligands are a key focus for developing selective and mutation-specific arrestin modulators.
• Further research into β-arrestin pathways can unlock novel therapeutic strategies.